AMGN, VRX And AGN, Pushing Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 37 points (0.2%) at 16,943 as of Wednesday, July 9, 2014, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,468 issues advancing vs. 1,471 declining with 161 unchanged.

The Drugs industry currently sits up 0.3% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Alexion Pharmaceuticals ( ALXN), up 2.2%, Vertex Pharmaceuticals ( VRTX), up 1.8%, Sanofi ( SNY), up 0.8% and GlaxoSmithKline ( GSK), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Amgen ( AMGN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Amgen is down $0.65 (-0.5%) to $119.31 on average volume. Thus far, 1.3 million shares of Amgen exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $118.92-$120.62 after having opened the day at $120.45 as compared to the previous trading day's close of $119.96.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $91.0 billion and is part of the health care sector. Shares are up 5.2% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Valeant Pharmaceuticals International ( VRX) is down $1.27 (-1.0%) to $120.90 on light volume. Thus far, 609,691 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 3.7 million shares. The stock has ranged in price between $120.46-$122.44 after having opened the day at $122.04 as compared to the previous trading day's close of $122.17.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Valeant Pharmaceuticals International has a market cap of $41.3 billion and is part of the health care sector. Shares are up 4.1% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and disappointing return on equity. Get the full Valeant Pharmaceuticals International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Allergan ( AGN) is down $1.06 (-0.6%) to $165.02 on light volume. Thus far, 351,309 shares of Allergan exchanged hands as compared to its average daily volume of 4.6 million shares. The stock has ranged in price between $164.45-$166.15 after having opened the day at $165.96 as compared to the previous trading day's close of $166.07.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $49.3 billion and is part of the health care sector. Shares are up 49.5% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Allergan a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Allergan Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists